跳至主要内容
临床试验/EUCTR2005-001830-34-GB
EUCTR2005-001830-34-GB进行中(未招募)1 期

The use of Myfortic in paediatric patients after liver transplantation

King's College Hospital0 个研究点目标入组 4 人开始时间: 2005年4月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Group 1: high risk for kidney dysfunction or pre-existing kidney dysfunction (GFR <80 ml/min/1.73m2). This inlcudes but is not limited to childen transplanted for hepatoblastoma, Alagilles syndrome, cystic fibrosis, alpha-1-antitrypsin deficiency, hyperoxuluria. The child is able to swallow tablets whole
  • Group 2: The child is experiencing gastrointestinal side effects of MMF requiring it to be reduced. The child is able to swallow tablets whole.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Parental consent and child assent has not been ascertained, pregnancy (all sexually active girls >12 years will have a pregnancy test prior to starting the study drug); hypersensitivity to mycophenolate

研究者

相似试验